文献速递心外重症与机械循环支持

微轴流左心室辅助装置与主动脉内球囊反搏作为心脏移植桥接的比较

Microaxial Left Ventricular Assist Device Versus Intraaortic Balloon Pump as a Bridge to Transplant.
PubMed 文献 · Ann Thorac Surg · 2021-08-19

该研究基于UNOS数据库2014年1月至2020年2月的数据,比较Impella与IABP作为心脏移植桥接的结局。结果显示两组移植后180天生存相似(调整HR 0.82,95%CI 0.38-1.78),但新分配系统下Impella支持者等待名单剔除风险更高(sHR 2.42,95%CI 1.19-4.92)。

要点

  • Impella使用率从2014年0.2%升至2020年2.6%,IABP从4.9%升至27.6%。
  • 移植后生存两组相似,调整HR 0.82(95%CI 0.38-1.78)。
  • 新系统下Impella支持者等待名单剔除风险高于IABP(sHR 2.42)。

核心结论

  • Impella与IABP支持的受者移植后生存相当,但Impella支持者术前状况更差。
  • 新分配系统下Impella支持的候选者等待名单剔除风险更高,需密切关注。

研究设计与样本

  • 回顾性队列研究,查询UNOS数据库2014年1月至2020年2月成人等待名单和/或移植患者。
  • 使用Royston趋势检验和χ2检验分析Impella与IABP使用的时间趋势。
  • 采用Fine-Gray竞争风险分析等待名单死亡率,Kaplan-Meier法和Cox比例风险模型分析移植后180天生存。

主要发现

  • Impella使用率从2014年0.2%增至2020年2.6%(P < .01),新分配系统下从0.4%增至2.2%(P < .01)。
  • IABP使用率从2014年4.9%增至2020年27.6%(P < .01),新分配系统下从6.7%增至26.6%(P < .01)。
  • 移植后生存两组相似(调整HR 0.82;95%CI 0.38-1.78),尽管Impella组术前机械通气更多(3.6% vs 1.1%,P = .01)且MELD-excluding INR评分更高(12.4 vs 9.5,P < .01)。
  • 新系统下Impella支持的候选者等待名单剔除风险高于IABP支持者(sHR 2.42;95%CI 1.19-4.92)。

临床怎么用

  • 对于心脏移植候选者,Impella与IABP作为桥接均可考虑,移植后生存相似。
  • 在新分配系统下,使用Impella桥接的候选者需更密切监测等待名单状态,警惕剔除风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Heart transplantation (HTx) candidates supported by Impella (Abiomed, Danvers, MA) or intraaortic balloon pump (IABP), who demonstrate evidence of cardiogenic shock, may qualify for waitlist status 2 without exception under the new donor heart allocation system. However limited data comparing Impella versus IABP as a bridge to HTx exist. METHODS: The United Network for Organ Sharing database was queried for adults listed and/or transplanted between January 2014 and February 2020. Temporal trends regarding Impella and IABP use were analyzed using the Royston trend test and χ2 test. Waitlist mortality was examined using Fine-Gray competing risks analysis. Post-HTx 180-day survival was analyzed using the Kaplan-Meier method and Cox proportional hazards models. RESULTS: Impella use increased from 0.2% in 2014 to 2.6% in 2020 (P < .01) and from 0.4% to 2.2% (P < .01) under the new allocation system. IABP use increased from 4.9% in 2014 to 27.6% in 2020 (P < .01) and from 6.7% to 26.6% (P < .01) under the new allocation system. Post-HTx survival was similar between groups (adjusted hazard ratio, 0.82; 95% CI, 0.38-1.78) despite more preoperative ventilation (3.6% vs 1.1%, P = .01) and higher model for end-stage liver disease excluding international normalized ratio scores (12.4 vs 9.5, P < .01) among Impella-supported recipients. Under the new system Impella-supported candidates were at higher risk of waitlist delisting compared with IABP-supported candidates (subhazard ratio, 2.42; 95% CI, 1.19-4.92). CONCLUSIONS: Post-HTx survival is comparable between Impella-supported and IABP-supported recipients despite worse preoperative profiles among Impella-supported recipients. Higher risk of waitlist delisting among Impella-supported candidates under the new allocation system requires close attention.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Nordan T, Critsinelis AC, Mahrokhian SH, et al. Microaxial Left Ventricular Assist Device Versus Intraaortic Balloon Pump as a Bridge to Transplant. Ann Thorac Surg. 2021. PMID: 34419433. doi:10.1016/j.athoracsur.2021.07.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。